Role of phospholipase C in cell invasion and metastasis

Advances in Biological Regulation

Volumn 53, Issue 3, 2013, Pages 309-318

  Lattanzio, Rossano ^a   Piantelli, Mauro ^a   Falasca, Marco ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPASE C GAMMA; PLCG1 PROTEIN, HUMAN;

ANIMAL; CELL MOTION; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; TUMOR INVASION;

ANIMALS; CELL MOVEMENT; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PHOSPHOLIPASE C GAMMA;

EID: 84885734781     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2013.07.006     Document Type: Review

References (95)

1. Andre F., Bachelot T., Campone M., Dalenc F., Perez-Garcia J.M., Hurvitz S.A., et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013, DOI: 10.1158/1078-0432.CCR-13-0190.
2. Arteaga C.L., Johnson M.D., Todderud G., Coffey R.J., Carpenter G., Page D.L. Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci U S A 1991, 88:10435-10439.
3. Balz L.M., Bartkowiak K., Andreas A., Pantel K., Niggemann B., Zanker K.S., et al. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-gamma1 signalling in breast cancer cell migration and dissemination. J Pathol 2012, 227:234-244.
4. Bayascas J.R., Leslie N.R., Parsons R., Fleming S., Alessi D.R. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol 2005, 15:1839-1846.
5. Cao Y., Li H., Liu H., Zhang M., Hua Z., Ji H., et al. LKB1 regulates TCR-mediated PLCgamma1 activation and thymocyte positive selection. Embo J 2011, 30:2083-2093.
6. Carpenter G., Ji Q. Phospholipase C-gamma as a signal-transducing element. Exp Cell Res 1999, 253:15-24.
7. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313.
8. Chen P., Xie H., Sekar M.C., Gupta K., Wells A. Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol 1994, 127:847-857.
9. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009, 106:13820-13825.
10. Davies G., Martin T.A., Ye L., Lewis-Russell J.M., Mason M.D., Jiang W.G. Phospholipase-C gamma-1 (PLCgamma-1) is critical in hepatocyte growth factor induced invitro invasion and migration without affecting the growth of prostate cancer cells. Urol Oncol 2008, 26:386-391.
11. Dey J.H., Bianchi F., Voshol J., Bonenfant D., Oakeley E.J., Hynes N.E. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010, 70:4151-4162.
12. DiGiovanna M.P., Stern D.F., Edgerton S.M., Whalen S.G., Moore D., Thor A.D. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005, 23:1152-1160.
13. Eccles S.A. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001, 6:393-406.
14. Faenza I., Bregoli L., Ramazzotti G., Gaboardi G., Follo M.Y., Mongiorgi S., et al. Nuclear phospholipase C beta1 and cellular differentiation. Front Biosci 2008, 13:2452-2463.
15. Falasca M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des 2010, 16:1410-1416.
16. Falasca M., Logan S.K., Lehto V.P., Baccante G., Lemmon M.A., Schlessinger J. Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. Embo J 1998, 17:414-422.
17. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008, 10:R25.
18. Finlay D.K., Sinclair L.V., Feijoo C., Waugh C.M., Hagenbeek T.J., Spits H., et al. Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes. J Exp Med 2009, 206:2441-2454.
19. Fiume R., Keune W.J., Faenza I., Bultsma Y., Ramazzotti G., Jones D.R., et al. Nuclear phosphoinositides: location, regulation and function. Subcell Biochem 2012, 59:335-361.
20. Fu G., Chen Y., Yu M., Podd A., Schuman J., He Y., et al. Phospholipase C{gamma}1 is essential for T cell development, activation, and tolerance. J Exp Med 2010, 207:309-318.
21. Goetz R., Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 2013, 14:166-180.
22. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
23. Higuchi M., Onishi K., Kikuchi C., Gotoh Y. Scaffolding function of PAK in the PDK1-Akt pathway. Nat Cell Biol 2008, 10:1356-1364.
24. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003, 100:8933-8938.
25. Hsieh A.C., Moasser M.M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007, 97:453-457.
26. Huang J., Manning B.D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009, 37:217-222.
27. Huang W., Barrett M., Hajicek N., Hicks S., Harden T.K., Sondek J., et al. Small molecule inhibitors of phospholipase C from a novel high-throughput screen. J Biol Chem 2009, 288:5840-5848.
28. Itoh N., Ornitz D.M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. JBiochem 2011, 149:121-130.
29. Jain V.K., Turner N.C. Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. Breast Cancer Res 2012, 14:208.
30. Jang H.J., Yang Y.R., Kim J.K., Choi J.H., Seo Y.K., Lee Y.H., et al. Phospholipase C-gamma1 involved in brain disorders. Adv Biol Regul 2013, 53:51-62.
31. Ji Q.S., Winnier G.E., Niswender K.D., Horstman D., Wisdom R., Magnuson M.A., et al. Essential role of the tyrosine kinase substrate phospholipase C-gamma1 in mammalian growth and development. Proc Natl Acad Sci U S A 1997, 94:2999-3003.
32. Jones N.P., Katan M. Role of phospholipase Cgamma1 in cell spreading requires association with a beta-Pix/GIT1-containing complex, leading to activation of Cdc42 and Rac1. Mol Cell Biol 2007, 27:5790-5805.
33. Kadamur G., Ross E.M. Mammalian phospholipase C. Annu Rev Physiol 2013, 75:127-154.
34. Kassis J., Moellinger J., Lo H., Greenberg N.M., Kim H.G., Wells A. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Clin Cancer Res 1999, 5:2251-2260.
35. Katan M. Families of phosphoinositide-specific phospholipase C: structure and function. Biochim Biophys Acta 1998, 1436:5-17.
36. Keune W., Bultsma Y., Sommer L., Jones D., Divecha N. Phosphoinositide signalling in the nucleus. Adv Enzym Regul 2011, 51:91-99.
37. Kim H.K., Kim J.W., Zilberstein A., Margolis B., Kim J.G., Schlessinger J., et al. PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254. Cell 1991, 65:435-441.
38. Kim M.J., Chang J.S., Park S.K., Hwang J.I., Ryu S.H., Suh P.G. Direct interaction of SOS1 Ras exchange protein with the SH3 domain of phospholipase C-gamma1. Biochemistry 2000, 39:8674-8682.
39. Kruser T.J., Wheeler D.L. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010, 316:1083-1100.
40. Lattanzio R., Marchisio M., La Sorda R., Tinari N., Falasca M., Alberti S., et al. Overexpression of activated phospholipase Cgamma1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy. Int J Cancer 2013, 132:1022-1031.
41. Li S., Wang Q., Wang Y., Chen X., Wang Z. PLC-gamma1 and Rac1 coregulate EGF-induced cytoskeleton remodeling and cell migration. Mol Endocrinol 2009, 23:901-913.
42. Liao H.J., Kume T., McKay C., Xu M.J., Ihle J.N., Carpenter G. Absence of erythrogenesis and vasculogenesis in Plcg1-deficient mice. J Biol Chem 2002, 277:9335-9341.
43. Lim M.A., Yang L., Zheng Y., Wu H., Dong L.Q., Liu F. Roles of PDK-1 and PKN in regulating cell migration and cortical actin formation of PTEN-knockout cells. Oncogene 2004, 23:9348-9358.
44. Liu Y., Wang J., Wu M., Wan W., Sun R., Yang D., et al. Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells. Mol Cancer Res 2009, 7:944-954.
45. Maffucci T., Falasca M. Phosphoinositide 3-kinase-dependent regulation of phospholipase Cgamma. Biochem Soc Trans 2007, 35:229-230.
46. Maffucci T., Raimondi C., Abu-Hayyeh S., Dominguez V., Sala G., Zachary I., et al. A phosphoinositide 3-kinase/phospholipase Cgamma1 pathway regulates fibroblast growth factor-induced capillary tube formation. PLoS One 2009, 4:e8285.
47. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
48. Manzoli L., Martelli A.M., Billi A.M., Faenza I., Fiume R., Cocco L. Nuclear phospholipase C: involvement in signal transduction. Prog Lipid Res 2005, 44:185-206.
49. Maurer M., Su T., Saal L.H., Koujak S., Hopkins B.D., Barkley C.R., et al. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res 2009, 69:6299-6306.
50. Mora A., Komander D., van Aalten D.M., Alessi D.R. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 2004, 15:161-170.
51. Mouneimne G., Soon L., DesMarais V., Sidani M., Song X., Yip S.C., et al. Phospholipase C and cofilin are required for carcinoma cell directionality in response to EGF stimulation. J Cell Biol 2004, 166:697-708.
52. Munro N.P., Knowles M.A. Fibroblast growth factors and their receptors in transitional cell carcinoma. J Urol 2003, 169:675-682.
53. Nanney L.B., Gates R.E., Todderud G., King L.E., Carpenter G. Altered distribution of phospholipase C-gamma 1 in benign hyperproliferative epidermal diseases. Cell Growth Differ 1992, 3:233-239.
54. Nguyen D.X., Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007, 8:341-352.
55. Nishibe S., Wahl M.I., Hernandez-Sotomayor S.M., Tonks N.K., Rhee S.G., Carpenter G. Increase of the catalytic activity of phospholipase C-gamma 1 by tyrosine phosphorylation. Science 1990, 250:1253-1256.
56. Noh D.Y., Lee Y.H., Kim S.S., Kim Y.I., Ryu S.H., Suh P.G., et al. Elevated content of phospholipase C-gamma 1 in colorectal cancer tissues. Cancer 1994, 73:36-41.
57. Nozawa H., Howell G., Suzuki S., Zhang Q., Qi Y., Klein-Seetharaman J., et al. Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res 2008, 14:4336-4344.
58. Ou Y., Ma L., Dong L., Ma L., Zhao Z., Ma L., et al. Migfilin protein promotes migration and invasion in human glioma through epidermal growth factor receptor-mediated phospholipase C-gamma and STAT3 protein signaling pathways. J Biol Chem 2012, 287:32394-32405.
59. Park J.B., Lee C.S., Jang J.H., Ghim J., Kim Y.J., You S., et al. Phospholipase signalling networks in cancer. Nat Rev Cancer 2012, 12:782-792.
60. Park J.G., Lee Y.H., Kim S.S., Park K.J., Noh D.Y., Ryu S.H., et al. Overexpression of phospholipase C-gamma 1 in familial adenomatous polyposis. Cancer Res 1994, 54:2240-2244.
61. Park S.Y., Lee H.E., Li H., Shipitsin M., Gelman R., Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010, 16:876-887.
62. Peng J., Liao L., Chen Y., Pennypacker S.D., Gao X., Zhou S.H., et al. Two distinct mechanisms by which phospholipase C-gamma1 mediates epidermal growth factor-induced keratinocyte migration and proliferation. J Dermatol Sci 2012, 67:199-202.
63. Piccolo E., Innominato P.F., Mariggio M.A., Maffucci T., Iacobelli S., Falasca M. The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Oncogene 2002, 21:6520-6529.
64. Pinner S., Sahai E. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol 2008, 10:127-137.
65. Poulin B., Sekiya F., Rhee S.G. Intramolecular interaction between phosphorylated tyrosine-783 and the C-terminal Src homology 2 domain activates phospholipase C-gamma1. Proc Natl Acad Sci U S A 2005, 102:4276-4281.
66. Primo L., di Blasio L., Roca C., Droetto S., Piva R., Schaffhausen B., et al. Essential role of PDK1 in regulating endothelial cell migration. J Cell Biol 2007, 176:1035-1047.
67. Raimondi C., Falasca M. Phosphoinositides signalling in cancer: focus on PI3K and PLC. Adv Biol Regul 2012, 52:166-182.
68. Raimondi C., Chikh A., Wheeler A.P., Maffucci T., Falasca M. A novel regulatory mechanism links PLCgamma1 to PDK1. J Cell Sci 2012, 125:3153-3163.
69. Raimondi C., Falasca M. Targeting PDK1 in cancer. Curr Med Chem 2011, 18:2763-2769.
70. Rebecchi M.J., Pentyala S.N. Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol Rev 2000, 80:1291-1335.
71. Sala G., Dituri F., Raimondi C., Previdi S., Maffucci T., Mazzoletti M., et al. Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res 2008, 68:10187-10196.
72. Sekiya F., Poulin B., Kim Y.J., Rhee S.G. Mechanism of tyrosine phosphorylation and activation of phospholipase C-gamma 1. Tyrosine 783 phosphorylation is not sufficient for lipase activation. J Biol Chem 2004, 279:32181-32190.
73. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
74. Shepard C.R., Kassis J., Whaley D.L., Kim H.G., Wells A. PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene 2007, 26:3020-3026.
75. Shien T., Doihara H., Hara H., Takahashi H., Yoshitomi S., Taira N., et al. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839). Breast Cancer 2004, 11:367-373.
76. Shirane M., Sawa H., Kobayashi Y., Nakano T., Kitajima K., Shinkai Y., et al. Deficiency of phospholipase C-gamma1 impairs renal development and hematopoiesis. Development 2001, 128:5173-5180.
77. Tenhagen M., van Diest P.J., Ivanova I.A., van der Wall E., van der Groep P. Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. Endocr Relat Cancer 2012, 19:R115-R129.
78. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
79. Tomlinson D.C., Knowles M.A., Speirs V. Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer 2012, 130:2857-2866.
80. Tomlinson D.C., Baxter E.W., Loadman P.M., Hull M.A., Knowles M.A. FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCgamma/COX-2-mediated mechanisms. PLoS One 2012, 7:e38972.
81. Tomlinson D.C., Lamont F.R., Shnyder S.D., Knowles M.A. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 2009, 69:4613-4620.
82. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10:116-129.
83. Turner N., Pearson A., Sharpe R., Lambros M., Geyer F., Lopez-Garcia M.A., et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010, 70:2085-2094.
84. Uhlmann S., Zhang J.D., Schwager A., Mannsperger H., Riazalhosseini Y., Burmester S., et al. miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene 2010, 29:4297-4306.
85. Wang W., Eddy R., Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer 2007, 7:429-440.
86. Wells A., Grandis J.R. Phospholipase C-gamma1 in tumor progression. Clin Exp Metastasis 2003, 20:285-290.
87. Xie Z., Chen Y., Liao E.Y., Jiang Y., Liu F.Y., Pennypacker S.D. Phospholipase C-gamma1 is required for the epidermal growth factor receptor-induced squamous cell carcinoma cell mitogenesis. Biochem Biophys Res Commun 2010, 397:296-300.
88. Xie Z., Chen Y., Pennypacker S.D., Zhou Z., Peng D. The SH3 domain, but not the catalytic domain, is required for phospholipase C-gamma1 to mediate epidermal growth factor-induced mitogenesis. Biochem Biophys Res Commun 2010, 398:719-722.
89. Xie Z., Peng J., Pennypacker S.D., Chen Y. Critical role for the catalytic activity of phospholipase C-gamma1 in epidermal growth factor-induced cell migration. Biochem Biophys Res Commun 2010, 399:425-428.
90. Xie Z., Jiang Y., Liao E.Y., Chen Y., Pennypacker S.D., Peng J., et al. PIKE mediates EGFR proliferative signaling in squamous cell carcinoma cells. Oncogene 2012, 31:5090-5098.
91. Yamaguchi H., Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 2007, 1773:642-652.
92. Yang Y.R., Choi J.H., Chang J.S., Kwon H.M., Jang H.J., Ryu S.H., et al. Diverse cellular and physiological roles of phospholipase C-gamma1. Adv Biol Regul 2012, 52:138-151.
93. Ye K., Aghdasi B., Luo H.R., Moriarity J.L., Wu F.Y., Hong J.J., et al. Phospholipase C gamma 1 is a physiological guanine nucleotide exchange factor for the nuclear GTPase PIKE. Nature 2002, 415:541-544.
94. Ye K., Ahn J.Y. Nuclear phosphoinositide signaling. Front Biosci 2008, 13:540-548.
95. Ye K., Hurt K.J., Wu F.Y., Fang M., Luo H.R., Hong J.J., et al. Pike. A nuclear gtpase that enhances PI3kinase activity and is regulated by protein 4.1N. Cell 2000, 103:919-930.